| Name | Number of Publications
|
Most Recent Publication
|
Publications by All Authors
|
Concept Score
|
Why?
|
|---|
| Endothelial Growth Factors | 40 | 2003 | 673 | 3.730 |
Why?
|
| Lymphokines | 39 | 2003 | 927 | 3.550 |
Why?
|
| Diabetic Retinopathy | 34 | 2022 | 1274 | 3.400 |
Why?
|
| Vascular Endothelial Growth Factor A | 72 | 2022 | 3492 | 2.940 |
Why?
|
| Aptamers, Nucleotide | 15 | 2009 | 165 | 1.970 |
Why?
|
| Macular Degeneration | 18 | 2022 | 1007 | 1.940 |
Why?
|
| Angiogenesis Inhibitors | 20 | 2022 | 2047 | 1.650 |
Why?
|
| Macular Edema | 9 | 2022 | 374 | 1.590 |
Why?
|
| Neovascularization, Pathologic | 22 | 2016 | 2645 | 1.550 |
Why?
|
| Choroidal Neovascularization | 17 | 2021 | 363 | 1.530 |
Why?
|
| Retinal Vessels | 23 | 2014 | 852 | 1.520 |
Why?
|
| Blood-Retinal Barrier | 13 | 2007 | 62 | 1.490 |
Why?
|
| Intercellular Adhesion Molecule-1 | 18 | 2007 | 1126 | 1.310 |
Why?
|
| Vascular Endothelial Growth Factors | 39 | 2003 | 748 | 1.180 |
Why?
|
| Retina | 27 | 2009 | 2659 | 1.170 |
Why?
|
| Corneal Neovascularization | 11 | 2008 | 185 | 1.120 |
Why?
|
| Wet Macular Degeneration | 2 | 2022 | 162 | 0.840 |
Why?
|
| Eye | 7 | 2015 | 712 | 0.810 |
Why?
|
| Leukostasis | 5 | 2007 | 23 | 0.770 |
Why?
|
| Cornea | 15 | 2008 | 1333 | 0.760 |
Why?
|
| Vitreous Body | 19 | 2024 | 399 | 0.750 |
Why?
|
| Endothelium, Vascular | 20 | 2006 | 4431 | 0.740 |
Why?
|
| Retinal Neovascularization | 6 | 2005 | 288 | 0.740 |
Why?
|
| Diabetes Mellitus, Experimental | 10 | 2007 | 1119 | 0.700 |
Why?
|
| Choroid | 9 | 2014 | 360 | 0.670 |
Why?
|
| Eye Diseases | 6 | 2009 | 653 | 0.650 |
Why?
|
| Pigment Epithelium of Eye | 8 | 2004 | 209 | 0.650 |
Why?
|
| Rats, Long-Evans | 15 | 2007 | 383 | 0.630 |
Why?
|
| Capillary Permeability | 12 | 2003 | 773 | 0.560 |
Why?
|
| Proto-Oncogene Proteins c-sis | 2 | 2015 | 255 | 0.530 |
Why?
|
| Hypoxia-Inducible Factor 1 | 2 | 2015 | 193 | 0.530 |
Why?
|
| Angiopoietin-2 | 2 | 2022 | 172 | 0.520 |
Why?
|
| Leukocytes | 11 | 2003 | 2026 | 0.520 |
Why?
|
| Intercellular Signaling Peptides and Proteins | 5 | 2003 | 1651 | 0.510 |
Why?
|
| Visual Acuity | 16 | 2022 | 2672 | 0.510 |
Why?
|
| Receptors, Vascular Endothelial Growth Factor | 4 | 2022 | 664 | 0.510 |
Why?
|
| Complement Pathway, Alternative | 1 | 2015 | 113 | 0.500 |
Why?
|
| Cell Adhesion | 13 | 2009 | 3087 | 0.490 |
Why?
|
| Ischemia | 7 | 2003 | 1882 | 0.490 |
Why?
|
| Iris | 7 | 1998 | 232 | 0.480 |
Why?
|
| Fluorescein-5-isothiocyanate | 4 | 2003 | 223 | 0.470 |
Why?
|
| Eye Injuries | 4 | 2006 | 227 | 0.440 |
Why?
|
| Drug Delivery Systems | 6 | 2021 | 2226 | 0.420 |
Why?
|
| Antibodies, Monoclonal | 12 | 2022 | 9177 | 0.420 |
Why?
|
| Sclera | 4 | 2003 | 190 | 0.410 |
Why?
|
| RNA, Messenger | 22 | 2008 | 12795 | 0.410 |
Why?
|
| Fluorescein Angiography | 20 | 2014 | 1059 | 0.390 |
Why?
|
| Intravitreal Injections | 7 | 2024 | 385 | 0.380 |
Why?
|
| Injections | 14 | 2009 | 830 | 0.370 |
Why?
|
| Recombinant Fusion Proteins | 5 | 2022 | 3734 | 0.360 |
Why?
|
| Rats | 26 | 2007 | 23742 | 0.360 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-1 | 6 | 2008 | 558 | 0.340 |
Why?
|
| Gene Expression | 9 | 2001 | 7581 | 0.340 |
Why?
|
| Edema | 3 | 2022 | 766 | 0.340 |
Why?
|
| Oligonucleotides | 4 | 2005 | 582 | 0.310 |
Why?
|
| Animals | 82 | 2014 | 168459 | 0.310 |
Why?
|
| Keratitis | 3 | 2000 | 241 | 0.290 |
Why?
|
| Glaucoma, Neovascular | 2 | 1998 | 37 | 0.290 |
Why?
|
| Retinal Vein Occlusion | 4 | 2011 | 149 | 0.280 |
Why?
|
| Models, Econometric | 1 | 2007 | 216 | 0.280 |
Why?
|
| Complement System Proteins | 1 | 2010 | 736 | 0.270 |
Why?
|
| Retinal Diseases | 3 | 2003 | 705 | 0.250 |
Why?
|
| Evans Blue | 3 | 2001 | 42 | 0.250 |
Why?
|
| Blotting, Northern | 9 | 2003 | 1545 | 0.250 |
Why?
|
| Ocular Physiological Phenomena | 1 | 2005 | 67 | 0.240 |
Why?
|
| Fuchs' Endothelial Dystrophy | 2 | 2000 | 103 | 0.240 |
Why?
|
| Nitric Oxide Synthase | 3 | 2002 | 908 | 0.240 |
Why?
|
| Immunoenzyme Techniques | 7 | 2007 | 1705 | 0.230 |
Why?
|
| Receptors, Leukocyte-Adhesion | 2 | 2002 | 52 | 0.230 |
Why?
|
| Retinal Degeneration | 2 | 2006 | 413 | 0.230 |
Why?
|
| Fibroblast Growth Factor 2 | 7 | 2009 | 592 | 0.230 |
Why?
|
| Insulin-Like Growth Factor I | 3 | 2004 | 1934 | 0.220 |
Why?
|
| Macaca fascicularis | 12 | 2009 | 903 | 0.220 |
Why?
|
| Enzyme-Linked Immunosorbent Assay | 9 | 2014 | 3810 | 0.220 |
Why?
|
| Anti-Inflammatory Agents, Non-Steroidal | 3 | 2008 | 2273 | 0.220 |
Why?
|
| Aqueous Humor | 3 | 2000 | 153 | 0.220 |
Why?
|
| Mice, Inbred C57BL | 23 | 2014 | 22169 | 0.210 |
Why?
|
| Infusion Pumps, Implantable | 2 | 2002 | 158 | 0.210 |
Why?
|
| Receptors, Immunologic | 2 | 2007 | 1410 | 0.210 |
Why?
|
| Endothelium, Corneal | 3 | 2003 | 215 | 0.210 |
Why?
|
| Rabbits | 10 | 2009 | 4772 | 0.210 |
Why?
|
| JNK Mitogen-Activated Protein Kinases | 1 | 2004 | 441 | 0.210 |
Why?
|
| Neutrophils | 5 | 2003 | 3767 | 0.210 |
Why?
|
| Coloring Agents | 3 | 2001 | 562 | 0.200 |
Why?
|
| Drug Implants | 2 | 2019 | 230 | 0.200 |
Why?
|
| Conjunctiva | 2 | 2003 | 479 | 0.200 |
Why?
|
| Plasminogen | 1 | 2002 | 144 | 0.200 |
Why?
|
| Retinitis | 1 | 2002 | 36 | 0.200 |
Why?
|
| Vascular Endothelial Growth Factor Receptor-2 | 2 | 2007 | 546 | 0.200 |
Why?
|
| Membrane Glycoproteins | 5 | 2003 | 3702 | 0.190 |
Why?
|
| Sialoglycoproteins | 1 | 2002 | 315 | 0.190 |
Why?
|
| Macula Lutea | 2 | 2022 | 177 | 0.190 |
Why?
|
| Gene Expression Regulation | 4 | 2007 | 11903 | 0.190 |
Why?
|
| Polyglycolic Acid | 1 | 2003 | 406 | 0.190 |
Why?
|
| Drug Therapy, Combination | 3 | 2009 | 6310 | 0.190 |
Why?
|
| Capillary Leak Syndrome | 1 | 2001 | 34 | 0.190 |
Why?
|
| Dextrans | 2 | 2000 | 574 | 0.190 |
Why?
|
| Eye Proteins | 2 | 2001 | 633 | 0.190 |
Why?
|
| Conjunctivitis, Viral | 1 | 2000 | 6 | 0.180 |
Why?
|
| Serum Albumin, Bovine | 2 | 2003 | 321 | 0.180 |
Why?
|
| Ketorolac | 1 | 2000 | 94 | 0.170 |
Why?
|
| Cyclic CMP | 1 | 1999 | 6 | 0.170 |
Why?
|
| Ophthalmic Solutions | 2 | 2000 | 313 | 0.170 |
Why?
|
| Epithelium, Corneal | 1 | 2002 | 253 | 0.170 |
Why?
|
| Integrin alpha5beta1 | 2 | 2009 | 37 | 0.170 |
Why?
|
| Goblet Cells | 1 | 2003 | 298 | 0.170 |
Why?
|
| Disease Models, Animal | 16 | 2014 | 18252 | 0.170 |
Why?
|
| Retinal Vein | 2 | 2006 | 47 | 0.170 |
Why?
|
| Humans | 80 | 2024 | 761504 | 0.160 |
Why?
|
| Mice | 31 | 2014 | 81525 | 0.160 |
Why?
|
| Antibodies, Bispecific | 1 | 2022 | 196 | 0.160 |
Why?
|
| Transfection | 3 | 2002 | 5774 | 0.160 |
Why?
|
| Retinal Pigment Epithelium | 2 | 2014 | 303 | 0.160 |
Why?
|
| Proto-Oncogene Proteins | 5 | 2004 | 4511 | 0.160 |
Why?
|
| Receptor Protein-Tyrosine Kinases | 3 | 2002 | 1626 | 0.150 |
Why?
|
| Receptors, Growth Factor | 1 | 1999 | 326 | 0.150 |
Why?
|
| Cattle | 8 | 2003 | 3849 | 0.150 |
Why?
|
| Conjunctivitis, Inclusion | 1 | 1998 | 3 | 0.150 |
Why?
|
| Trachoma | 1 | 1998 | 18 | 0.150 |
Why?
|
| Dose-Response Relationship, Drug | 10 | 2009 | 10766 | 0.150 |
Why?
|
| Retinal Ganglion Cells | 4 | 2009 | 811 | 0.150 |
Why?
|
| Corneal Dystrophies, Hereditary | 2 | 2001 | 64 | 0.150 |
Why?
|
| Immunoglobulin G | 4 | 2007 | 4544 | 0.150 |
Why?
|
| Male | 50 | 2022 | 360804 | 0.140 |
Why?
|
| Lactic Acid | 1 | 2003 | 1139 | 0.140 |
Why?
|
| Blotting, Western | 5 | 2004 | 5035 | 0.140 |
Why?
|
| Fundus Oculi | 5 | 2019 | 556 | 0.140 |
Why?
|
| Acridine Orange | 3 | 2000 | 28 | 0.130 |
Why?
|
| Inflammation | 5 | 2010 | 10773 | 0.130 |
Why?
|
| Insulin | 2 | 2002 | 6596 | 0.130 |
Why?
|
| Plasmids | 1 | 2001 | 2269 | 0.130 |
Why?
|
| Retinal Hemorrhage | 1 | 1996 | 95 | 0.130 |
Why?
|
| Reverse Transcriptase Polymerase Chain Reaction | 5 | 2004 | 4575 | 0.130 |
Why?
|
| Delayed-Action Preparations | 2 | 2019 | 962 | 0.130 |
Why?
|
| Angiogenesis Inducing Agents | 1 | 1998 | 278 | 0.130 |
Why?
|
| Corneal Transplantation | 1 | 2000 | 321 | 0.130 |
Why?
|
| Photography | 1 | 2019 | 532 | 0.130 |
Why?
|
| Hyperoxia | 1 | 1997 | 258 | 0.130 |
Why?
|
| Polymers | 1 | 2003 | 1617 | 0.130 |
Why?
|
| Biocompatible Materials | 2 | 2003 | 1685 | 0.120 |
Why?
|
| Mice, Transgenic | 6 | 2007 | 9539 | 0.120 |
Why?
|
| Cost-Benefit Analysis | 1 | 2007 | 5492 | 0.120 |
Why?
|
| Nitric Oxide Synthase Type III | 3 | 2002 | 705 | 0.120 |
Why?
|
| In Situ Hybridization | 5 | 1999 | 1900 | 0.120 |
Why?
|
| Protein Isoforms | 3 | 2004 | 1699 | 0.120 |
Why?
|
| Fas Ligand Protein | 3 | 2003 | 216 | 0.120 |
Why?
|
| Rats, Sprague-Dawley | 6 | 2001 | 8181 | 0.120 |
Why?
|
| Tumor Necrosis Factor-alpha | 3 | 2002 | 4352 | 0.110 |
Why?
|
| Nitric Oxide | 2 | 2002 | 2135 | 0.110 |
Why?
|
| DNA | 4 | 2003 | 7212 | 0.110 |
Why?
|
| Neoplasms | 2 | 2016 | 22170 | 0.110 |
Why?
|
| Culture Media, Conditioned | 3 | 2002 | 522 | 0.110 |
Why?
|
| NF-kappa B | 4 | 2004 | 2490 | 0.110 |
Why?
|
| Cell Division | 6 | 2003 | 4465 | 0.110 |
Why?
|
| Epidermolysis Bullosa Simplex | 1 | 1993 | 12 | 0.110 |
Why?
|
| Electrophoretic Mobility Shift Assay | 2 | 2004 | 293 | 0.110 |
Why?
|
| Cells, Cultured | 10 | 2003 | 18965 | 0.110 |
Why?
|
| Neuroprotective Agents | 3 | 2009 | 957 | 0.110 |
Why?
|
| Treatment Outcome | 12 | 2022 | 64680 | 0.100 |
Why?
|
| Recombinant Proteins | 8 | 2007 | 6534 | 0.100 |
Why?
|
| Blood Platelets | 1 | 2003 | 2479 | 0.100 |
Why?
|
| Double-Blind Method | 9 | 2022 | 12341 | 0.100 |
Why?
|
| Half-Life | 2 | 2007 | 651 | 0.100 |
Why?
|
| Wounds, Nonpenetrating | 1 | 1998 | 807 | 0.090 |
Why?
|
| beta-Galactosidase | 2 | 2003 | 574 | 0.090 |
Why?
|
| Neovascularization, Physiologic | 4 | 2003 | 1349 | 0.090 |
Why?
|
| Tomography, Optical Coherence | 4 | 2019 | 2917 | 0.090 |
Why?
|
| Proteomics | 1 | 2024 | 3849 | 0.090 |
Why?
|
| Time Factors | 8 | 2016 | 39967 | 0.090 |
Why?
|
| Reactive Oxygen Species | 2 | 2003 | 2141 | 0.090 |
Why?
|
| Complement Inactivating Agents | 1 | 2010 | 53 | 0.080 |
Why?
|
| Peptide Fragments | 1 | 2002 | 5112 | 0.080 |
Why?
|
| Retinal Drusen | 1 | 2010 | 74 | 0.080 |
Why?
|
| Models, Immunological | 2 | 2010 | 513 | 0.080 |
Why?
|
| Cataract Extraction | 1 | 1994 | 467 | 0.080 |
Why?
|
| Hypoxia-Inducible Factor 1, alpha Subunit | 2 | 2004 | 619 | 0.080 |
Why?
|
| beta-Alanine | 1 | 2009 | 82 | 0.080 |
Why?
|
| Intraocular Pressure | 4 | 2008 | 1294 | 0.080 |
Why?
|
| Stem Cells | 1 | 2002 | 3522 | 0.080 |
Why?
|
| Eye Enucleation | 1 | 2009 | 128 | 0.080 |
Why?
|
| Permeability | 2 | 2002 | 723 | 0.080 |
Why?
|
| Propionates | 1 | 2009 | 183 | 0.080 |
Why?
|
| Luminescent Proteins | 2 | 2002 | 837 | 0.080 |
Why?
|
| Geographic Atrophy | 1 | 2010 | 91 | 0.080 |
Why?
|
| Vitreoretinopathy, Proliferative | 1 | 2009 | 76 | 0.080 |
Why?
|
| Antibodies, Blocking | 2 | 2000 | 243 | 0.080 |
Why?
|
| Leukocyte Count | 2 | 2004 | 1596 | 0.080 |
Why?
|
| Mice, Knockout | 7 | 2004 | 14414 | 0.070 |
Why?
|
| Complement Activation | 1 | 2010 | 445 | 0.070 |
Why?
|
| Optic Nerve Injuries | 1 | 2009 | 150 | 0.070 |
Why?
|
| Epithelium | 3 | 2002 | 1603 | 0.070 |
Why?
|
| Pyrrolidines | 1 | 2009 | 338 | 0.070 |
Why?
|
| Immunohistochemistry | 7 | 2009 | 11076 | 0.070 |
Why?
|
| Capillaries | 2 | 2003 | 755 | 0.070 |
Why?
|
| Clinical Trials as Topic | 4 | 2008 | 8002 | 0.070 |
Why?
|
| Gene Deletion | 3 | 2003 | 2665 | 0.070 |
Why?
|
| Nuclear Proteins | 1 | 2002 | 5796 | 0.070 |
Why?
|
| Sucralfate | 2 | 1996 | 12 | 0.070 |
Why?
|
| Mitogen-Activated Protein Kinases | 2 | 2002 | 1246 | 0.070 |
Why?
|
| Corneal Diseases | 1 | 1993 | 542 | 0.070 |
Why?
|
| Ophthalmoscopy | 2 | 2014 | 171 | 0.070 |
Why?
|
| Fluorescent Antibody Technique, Indirect | 3 | 2007 | 427 | 0.070 |
Why?
|
| Injections, Intraperitoneal | 1 | 2007 | 413 | 0.070 |
Why?
|
| Concanavalin A | 2 | 2003 | 190 | 0.070 |
Why?
|
| Collagen Type IV | 1 | 2006 | 126 | 0.070 |
Why?
|
| Green Fluorescent Proteins | 2 | 2002 | 2065 | 0.070 |
Why?
|
| Image Interpretation, Computer-Assisted | 1 | 2019 | 3357 | 0.070 |
Why?
|
| Artificial Intelligence | 1 | 2020 | 2578 | 0.060 |
Why?
|
| Aminopyridines | 1 | 2009 | 573 | 0.060 |
Why?
|
| Phosphopyruvate Hydratase | 1 | 1985 | 127 | 0.060 |
Why?
|
| Random Allocation | 2 | 2003 | 2395 | 0.060 |
Why?
|
| Aged | 17 | 2022 | 169289 | 0.060 |
Why?
|
| Up-Regulation | 3 | 2003 | 4124 | 0.060 |
Why?
|
| Gene Expression Regulation, Developmental | 1 | 1996 | 3612 | 0.060 |
Why?
|
| Retinal Detachment | 1 | 2009 | 428 | 0.060 |
Why?
|
| Microspheres | 3 | 2003 | 784 | 0.060 |
Why?
|
| Aged, 80 and over | 10 | 2021 | 58976 | 0.060 |
Why?
|
| Female | 25 | 2022 | 392644 | 0.060 |
Why?
|
| Bromodeoxyuridine | 2 | 2002 | 311 | 0.060 |
Why?
|
| Antibodies | 2 | 2006 | 2418 | 0.060 |
Why?
|
| DNA-Binding Proteins | 1 | 2002 | 9606 | 0.060 |
Why?
|
| Proto-Oncogene Proteins c-akt | 2 | 2004 | 2455 | 0.060 |
Why?
|
| RNA | 3 | 2000 | 2726 | 0.060 |
Why?
|
| Markov Chains | 1 | 2007 | 966 | 0.060 |
Why?
|
| Proteinuria | 1 | 2007 | 607 | 0.060 |
Why?
|
| MAP Kinase Kinase 4 | 1 | 2004 | 149 | 0.060 |
Why?
|
| Photochemotherapy | 2 | 2008 | 823 | 0.060 |
Why?
|
| Conjunctival Diseases | 2 | 1997 | 110 | 0.060 |
Why?
|
| Phosphatidylinositol 3-Kinases | 2 | 2004 | 2865 | 0.060 |
Why?
|
| Diabetes Mellitus | 1 | 2002 | 5840 | 0.050 |
Why?
|
| Epithelial Cells | 3 | 2003 | 3673 | 0.050 |
Why?
|
| Galactose | 1 | 2004 | 297 | 0.050 |
Why?
|
| Optic Nerve Diseases | 1 | 2007 | 342 | 0.050 |
Why?
|
| History, 21st Century | 1 | 2009 | 1567 | 0.050 |
Why?
|
| Fluorophotometry | 1 | 2002 | 40 | 0.050 |
Why?
|
| Transcription Factor AP-1 | 1 | 2004 | 321 | 0.050 |
Why?
|
| Cell Migration Inhibition | 1 | 2002 | 97 | 0.050 |
Why?
|
| Angiostatins | 1 | 2002 | 64 | 0.050 |
Why?
|
| Molecular Biology | 1 | 2006 | 576 | 0.050 |
Why?
|
| Circular Dichroism | 1 | 2003 | 344 | 0.050 |
Why?
|
| Ophthalmology | 1 | 2009 | 550 | 0.050 |
Why?
|
| Erythropoietin | 1 | 2007 | 719 | 0.050 |
Why?
|
| DNA Primers | 4 | 2001 | 2819 | 0.050 |
Why?
|
| Jurkat Cells | 1 | 2004 | 740 | 0.050 |
Why?
|
| Lasers | 1 | 2006 | 952 | 0.050 |
Why?
|
| Middle Aged | 16 | 2022 | 220895 | 0.050 |
Why?
|
| Umbilical Veins | 1 | 2003 | 426 | 0.050 |
Why?
|
| Immunoglobulin M | 1 | 2007 | 1527 | 0.050 |
Why?
|
| Carcinoma, Lewis Lung | 1 | 2002 | 108 | 0.050 |
Why?
|
| Thiazines | 1 | 2002 | 38 | 0.050 |
Why?
|
| Kinetics | 2 | 2002 | 6374 | 0.050 |
Why?
|
| Immunoglobulin Fragments | 1 | 2002 | 84 | 0.050 |
Why?
|
| Fibrosis | 1 | 2009 | 2049 | 0.050 |
Why?
|
| Receptors, Interleukin-2 | 1 | 2003 | 562 | 0.050 |
Why?
|
| Apoptosis | 5 | 2007 | 9486 | 0.050 |
Why?
|
| Angiopoietin-1 | 1 | 2002 | 122 | 0.050 |
Why?
|
| Antioxidants | 3 | 2003 | 1668 | 0.050 |
Why?
|
| Nitrites | 1 | 2002 | 159 | 0.050 |
Why?
|
| Animals, Newborn | 2 | 2006 | 2678 | 0.050 |
Why?
|
| NG-Nitroarginine Methyl Ester | 1 | 2002 | 260 | 0.050 |
Why?
|
| Mitogen-Activated Protein Kinase Kinases | 1 | 2004 | 641 | 0.050 |
Why?
|
| Receptors, Interleukin-1 | 1 | 2002 | 262 | 0.050 |
Why?
|
| Liver Regeneration | 1 | 2003 | 213 | 0.050 |
Why?
|
| Retinopathy of Prematurity | 1 | 2006 | 439 | 0.050 |
Why?
|
| Expressed Sequence Tags | 1 | 2001 | 250 | 0.050 |
Why?
|
| Promoter Regions, Genetic | 3 | 2004 | 5789 | 0.050 |
Why?
|
| 14-3-3 Proteins | 1 | 2002 | 220 | 0.050 |
Why?
|
| Chemotaxis, Leukocyte | 1 | 2004 | 662 | 0.050 |
Why?
|
| History, 20th Century | 1 | 2009 | 2767 | 0.050 |
Why?
|
| Tyrosine 3-Monooxygenase | 1 | 2002 | 370 | 0.050 |
Why?
|
| Interleukin 1 Receptor Antagonist Protein | 1 | 2002 | 299 | 0.050 |
Why?
|
| Administration, Topical | 2 | 2000 | 704 | 0.050 |
Why?
|
| Enzyme Inhibitors | 3 | 2003 | 3712 | 0.050 |
Why?
|
| Molecular Weight | 2 | 2000 | 2186 | 0.050 |
Why?
|
| Antigens, CD34 | 1 | 2003 | 658 | 0.050 |
Why?
|
| Cell Count | 2 | 2003 | 1835 | 0.050 |
Why?
|
| Receptors, CCR5 | 1 | 2003 | 486 | 0.050 |
Why?
|
| Needles | 1 | 2024 | 451 | 0.050 |
Why?
|
| Proliferating Cell Nuclear Antigen | 2 | 2003 | 283 | 0.040 |
Why?
|
| Nitric Oxide Synthase Type II | 1 | 2002 | 517 | 0.040 |
Why?
|
| Diffusion Chambers, Culture | 1 | 2000 | 49 | 0.040 |
Why?
|
| Pinocytosis | 1 | 2000 | 62 | 0.040 |
Why?
|
| Reperfusion Injury | 1 | 2007 | 1023 | 0.040 |
Why?
|
| Gelsolin | 1 | 2001 | 189 | 0.040 |
Why?
|
| Interviews as Topic | 1 | 2007 | 2696 | 0.040 |
Why?
|
| Cell Survival | 2 | 2007 | 5791 | 0.040 |
Why?
|
| Receptors, Chemokine | 1 | 2003 | 652 | 0.040 |
Why?
|
| Epitopes | 1 | 2006 | 2503 | 0.040 |
Why?
|
| Cyclooxygenase Inhibitors | 1 | 2002 | 361 | 0.040 |
Why?
|
| Transport Vesicles | 1 | 2000 | 81 | 0.040 |
Why?
|
| Electroretinography | 2 | 2014 | 525 | 0.040 |
Why?
|
| Vascular Cell Adhesion Molecule-1 | 1 | 2002 | 691 | 0.040 |
Why?
|
| Debridement | 1 | 2002 | 494 | 0.040 |
Why?
|
| Diabetes Complications | 1 | 2006 | 1315 | 0.040 |
Why?
|
| Hepatectomy | 1 | 2003 | 557 | 0.040 |
Why?
|
| Receptors, Tumor Necrosis Factor | 1 | 2002 | 585 | 0.040 |
Why?
|
| Neutrophil Activation | 1 | 2000 | 180 | 0.040 |
Why?
|
| Macrophage-1 Antigen | 1 | 2000 | 285 | 0.040 |
Why?
|
| Nitroprusside | 1 | 1999 | 272 | 0.040 |
Why?
|
| Nitric Oxide Donors | 1 | 1999 | 125 | 0.040 |
Why?
|
| Cell Death | 2 | 2002 | 1678 | 0.040 |
Why?
|
| Adrenal Cortex Hormones | 1 | 2008 | 1880 | 0.040 |
Why?
|
| Proteoglycans | 1 | 2002 | 803 | 0.040 |
Why?
|
| Aging | 1 | 1998 | 8708 | 0.040 |
Why?
|
| Lymphocyte Function-Associated Antigen-1 | 1 | 2000 | 377 | 0.040 |
Why?
|
| Interleukin-1 | 1 | 2002 | 1248 | 0.040 |
Why?
|
| Neoplasm Transplantation | 1 | 2002 | 2016 | 0.040 |
Why?
|
| Drug Carriers | 1 | 2003 | 706 | 0.040 |
Why?
|
| Fluorescent Antibody Technique | 2 | 1993 | 2469 | 0.040 |
Why?
|
| Tetradecanoylphorbol Acetate | 1 | 1999 | 817 | 0.040 |
Why?
|
| Keratoconus | 1 | 2000 | 112 | 0.040 |
Why?
|
| Clinical Competence | 1 | 1994 | 4792 | 0.040 |
Why?
|
| Tonometry, Ocular | 2 | 2009 | 235 | 0.040 |
Why?
|
| Cell Hypoxia | 2 | 1997 | 656 | 0.040 |
Why?
|
| Spectrometry, Fluorescence | 1 | 2000 | 685 | 0.040 |
Why?
|
| Hydrogen Peroxide | 2 | 2003 | 730 | 0.040 |
Why?
|
| Pyridines | 1 | 2009 | 2875 | 0.040 |
Why?
|
| 3T3 Cells | 1 | 1999 | 1085 | 0.040 |
Why?
|
| Integrins | 1 | 2002 | 834 | 0.040 |
Why?
|
| Ribonucleases | 1 | 1998 | 277 | 0.040 |
Why?
|
| Combined Modality Therapy | 1 | 2009 | 8529 | 0.040 |
Why?
|
| Glaucoma | 1 | 2007 | 1185 | 0.040 |
Why?
|
| E-Selectin | 1 | 1999 | 576 | 0.040 |
Why?
|
| Telomerase | 1 | 2002 | 745 | 0.030 |
Why?
|
| Blood Circulation | 1 | 1998 | 248 | 0.030 |
Why?
|
| Peroxidase | 1 | 2000 | 609 | 0.030 |
Why?
|
| P-Selectin | 1 | 1999 | 597 | 0.030 |
Why?
|
| Diagnostic Techniques, Ophthalmological | 1 | 2019 | 251 | 0.030 |
Why?
|
| Prospective Studies | 6 | 2011 | 54425 | 0.030 |
Why?
|
| Extracellular Matrix Proteins | 1 | 2001 | 829 | 0.030 |
Why?
|
| False Positive Reactions | 1 | 2019 | 957 | 0.030 |
Why?
|
| Dactinomycin | 1 | 1996 | 304 | 0.030 |
Why?
|
| Genes, ras | 1 | 1999 | 654 | 0.030 |
Why?
|
| Cycloheximide | 1 | 1996 | 343 | 0.030 |
Why?
|
| Cell Culture Techniques | 1 | 2004 | 1667 | 0.030 |
Why?
|
| Cell Line, Transformed | 1 | 1997 | 867 | 0.030 |
Why?
|
| Enzyme Activation | 1 | 2002 | 3597 | 0.030 |
Why?
|
| Transcription, Genetic | 3 | 2001 | 7594 | 0.030 |
Why?
|
| Trabecular Meshwork | 1 | 1996 | 101 | 0.030 |
Why?
|
| Protein Kinases | 1 | 2003 | 1608 | 0.030 |
Why?
|
| Organ Size | 1 | 2001 | 2254 | 0.030 |
Why?
|
| Transcriptional Activation | 1 | 2002 | 1756 | 0.030 |
Why?
|
| Randomized Controlled Trials as Topic | 2 | 2019 | 10209 | 0.030 |
Why?
|
| Tissue Donors | 2 | 2009 | 2331 | 0.030 |
Why?
|
| Melanosis | 1 | 1997 | 93 | 0.030 |
Why?
|
| Light Coagulation | 1 | 1995 | 72 | 0.030 |
Why?
|
| Risk | 1 | 2007 | 9610 | 0.030 |
Why?
|
| Bacterial Vaccines | 1 | 1998 | 401 | 0.030 |
Why?
|
| Durapatite | 1 | 1996 | 163 | 0.030 |
Why?
|
| Reperfusion | 1 | 1996 | 271 | 0.030 |
Why?
|
| Oxygen | 2 | 1997 | 4227 | 0.030 |
Why?
|
| Microscopy, Electron | 2 | 2014 | 2561 | 0.030 |
Why?
|
| Superoxides | 1 | 1996 | 387 | 0.030 |
Why?
|
| Receptor, IGF Type 1 | 1 | 1997 | 379 | 0.030 |
Why?
|
| Flow Cytometry | 2 | 2009 | 5869 | 0.030 |
Why?
|
| Fluoroimmunoassay | 1 | 1994 | 30 | 0.030 |
Why?
|
| Lacrimal Apparatus Diseases | 1 | 1996 | 72 | 0.030 |
Why?
|
| Survival Analysis | 1 | 2007 | 10090 | 0.030 |
Why?
|
| Pregnancy Proteins | 1 | 1996 | 222 | 0.030 |
Why?
|
| Conjunctivitis | 1 | 1996 | 155 | 0.030 |
Why?
|
| Cryotherapy | 1 | 1995 | 159 | 0.030 |
Why?
|
| Thiazoles | 1 | 2002 | 1517 | 0.030 |
Why?
|
| Laser Coagulation | 3 | 2003 | 330 | 0.030 |
Why?
|
| Factor VIII | 1 | 1996 | 348 | 0.030 |
Why?
|
| Metalloendopeptidases | 1 | 1996 | 393 | 0.030 |
Why?
|
| Chlamydia Infections | 1 | 1998 | 365 | 0.030 |
Why?
|
| Polyethylenes | 1 | 1996 | 290 | 0.030 |
Why?
|
| Monocytes | 1 | 2003 | 2570 | 0.030 |
Why?
|
| Eyelid Diseases | 1 | 1996 | 157 | 0.030 |
Why?
|
| Antisense Elements (Genetics) | 1 | 1993 | 37 | 0.030 |
Why?
|
| Drug Administration Schedule | 1 | 2022 | 4853 | 0.030 |
Why?
|
| Microscopy, Confocal | 2 | 2014 | 1971 | 0.030 |
Why?
|
| RNA Probes | 1 | 1993 | 111 | 0.030 |
Why?
|
| Transcription Factors | 2 | 2004 | 12128 | 0.030 |
Why?
|
| Visual Pathways | 1 | 1998 | 551 | 0.030 |
Why?
|
| Keratoplasty, Penetrating | 1 | 1994 | 144 | 0.030 |
Why?
|
| Oligonucleotide Array Sequence Analysis | 1 | 2001 | 3778 | 0.030 |
Why?
|
| Comorbidity | 1 | 2007 | 10508 | 0.030 |
Why?
|
| Transforming Growth Factor beta | 1 | 2001 | 1961 | 0.030 |
Why?
|
| Cell Nucleus | 1 | 2002 | 2909 | 0.030 |
Why?
|
| Descemet Membrane | 1 | 1993 | 71 | 0.030 |
Why?
|
| Feasibility Studies | 1 | 2024 | 5247 | 0.030 |
Why?
|
| Macaca mulatta | 1 | 1999 | 2329 | 0.030 |
Why?
|
| Phosphorylation | 1 | 2004 | 8320 | 0.030 |
Why?
|
| Calculi | 1 | 1992 | 48 | 0.030 |
Why?
|
| Protease Inhibitors | 1 | 1996 | 754 | 0.030 |
Why?
|
| Interleukin-6 | 1 | 2002 | 3208 | 0.030 |
Why?
|
| Hemodynamics | 1 | 2003 | 4159 | 0.030 |
Why?
|
| Corneal Stroma | 1 | 1993 | 171 | 0.030 |
Why?
|
| Blood Glucose | 1 | 2007 | 6391 | 0.030 |
Why?
|
| Cell Movement | 2 | 2009 | 5203 | 0.020 |
Why?
|
| Basement Membrane | 1 | 1993 | 349 | 0.020 |
Why?
|
| Regulatory Sequences, Nucleic Acid | 1 | 1996 | 790 | 0.020 |
Why?
|
| Adult | 10 | 2013 | 221177 | 0.020 |
Why?
|
| Biopsy | 1 | 2024 | 6766 | 0.020 |
Why?
|
| Endothelium | 2 | 2003 | 765 | 0.020 |
Why?
|
| Cataract | 1 | 1998 | 832 | 0.020 |
Why?
|
| Collagen | 1 | 2000 | 2638 | 0.020 |
Why?
|
| Mutation, Missense | 1 | 2001 | 2571 | 0.020 |
Why?
|
| Blood Pressure | 1 | 2007 | 8481 | 0.020 |
Why?
|
| Blood Flow Velocity | 2 | 2007 | 1371 | 0.020 |
Why?
|
| Endothelial Cells | 1 | 2004 | 3548 | 0.020 |
Why?
|
| HIV Envelope Protein gp120 | 1 | 1996 | 914 | 0.020 |
Why?
|
| Oxygen Consumption | 1 | 1997 | 1866 | 0.020 |
Why?
|
| Glaucoma, Open-Angle | 1 | 1998 | 738 | 0.020 |
Why?
|
| Cell Line | 2 | 2009 | 15601 | 0.020 |
Why?
|
| Mice, Mutant Strains | 1 | 2014 | 1749 | 0.020 |
Why?
|
| Electrophoresis, Polyacrylamide Gel | 1 | 1993 | 1741 | 0.020 |
Why?
|
| Pilot Projects | 1 | 2024 | 8631 | 0.020 |
Why?
|
| Sickness Impact Profile | 1 | 2011 | 299 | 0.020 |
Why?
|
| Aspirin | 1 | 2002 | 3133 | 0.020 |
Why?
|
| Glucose | 1 | 2002 | 4346 | 0.020 |
Why?
|
| Prostheses and Implants | 1 | 1996 | 1271 | 0.020 |
Why?
|
| Virus Diseases | 1 | 1996 | 718 | 0.020 |
Why?
|
| California | 1 | 1994 | 1429 | 0.020 |
Why?
|
| Orbital Neoplasms | 1 | 1992 | 222 | 0.020 |
Why?
|
| Signal Transduction | 3 | 2014 | 23445 | 0.020 |
Why?
|
| Disease Progression | 1 | 2006 | 13506 | 0.020 |
Why?
|
| Thrombosis | 1 | 2003 | 2942 | 0.020 |
Why?
|
| Epiretinal Membrane | 1 | 2009 | 73 | 0.020 |
Why?
|
| Safety | 2 | 2005 | 1150 | 0.020 |
Why?
|
| Tissue Survival | 1 | 2009 | 119 | 0.020 |
Why?
|
| Insulin Resistance | 1 | 2003 | 3963 | 0.020 |
Why?
|
| Sequence Homology, Nucleic Acid | 2 | 2003 | 1058 | 0.020 |
Why?
|
| Neoplasm Proteins | 1 | 2001 | 3617 | 0.020 |
Why?
|
| Interferon Type I | 1 | 1992 | 562 | 0.020 |
Why?
|
| Infant, Newborn | 3 | 2024 | 26198 | 0.020 |
Why?
|
| Microcirculation | 2 | 2003 | 1273 | 0.020 |
Why?
|
| Bacterial Infections | 1 | 1996 | 1390 | 0.020 |
Why?
|
| Intraoperative Complications | 1 | 1994 | 1165 | 0.020 |
Why?
|
| Receptors, Erythropoietin | 1 | 2007 | 144 | 0.020 |
Why?
|
| Hemangioma | 1 | 1992 | 727 | 0.020 |
Why?
|
| Protein Denaturation | 1 | 2006 | 242 | 0.020 |
Why?
|
| Alternative Splicing | 3 | 1996 | 1093 | 0.020 |
Why?
|
| Memantine | 1 | 2007 | 108 | 0.020 |
Why?
|
| Thromboplastin | 1 | 2008 | 286 | 0.020 |
Why?
|
| Mice, Inbred DBA | 1 | 2007 | 621 | 0.020 |
Why?
|
| Immunochemistry | 1 | 1985 | 116 | 0.020 |
Why?
|
| Fibronectins | 1 | 2009 | 723 | 0.020 |
Why?
|
| T-Lymphocytes | 1 | 2003 | 10194 | 0.020 |
Why?
|
| Porphyrins | 1 | 2008 | 352 | 0.020 |
Why?
|
| Gene Expression Profiling | 1 | 2001 | 9420 | 0.020 |
Why?
|
| Models, Biological | 1 | 2002 | 9469 | 0.020 |
Why?
|
| Membrane Proteins | 1 | 2002 | 7856 | 0.020 |
Why?
|
| Blotting, Southern | 2 | 1996 | 777 | 0.020 |
Why?
|
| Organ Culture Techniques | 1 | 2007 | 794 | 0.020 |
Why?
|
| Cohort Studies | 1 | 2007 | 41487 | 0.020 |
Why?
|
| Postoperative Complications | 2 | 2000 | 15631 | 0.010 |
Why?
|
| Indocyanine Green | 1 | 2006 | 233 | 0.010 |
Why?
|
| Matrix Metalloproteinase 2 | 1 | 2006 | 459 | 0.010 |
Why?
|
| Drug Evaluation, Preclinical | 1 | 2009 | 1334 | 0.010 |
Why?
|
| Chromatography, High Pressure Liquid | 1 | 2008 | 1541 | 0.010 |
Why?
|
| Interferon-alpha | 2 | 2002 | 921 | 0.010 |
Why?
|
| Polymerase Chain Reaction | 3 | 2001 | 6075 | 0.010 |
Why?
|
| Retrospective Studies | 2 | 2019 | 80636 | 0.010 |
Why?
|
| Sensitivity and Specificity | 1 | 2019 | 14666 | 0.010 |
Why?
|
| Photosensitizing Agents | 1 | 2008 | 623 | 0.010 |
Why?
|
| Pericytes | 1 | 2006 | 293 | 0.010 |
Why?
|
| Connective Tissue | 1 | 1985 | 419 | 0.010 |
Why?
|
| Base Sequence | 3 | 2003 | 12441 | 0.010 |
Why?
|
| Sodium Hydroxide | 1 | 2003 | 37 | 0.010 |
Why?
|
| Optic Nerve | 1 | 2007 | 572 | 0.010 |
Why?
|
| Thioctic Acid | 1 | 2003 | 28 | 0.010 |
Why?
|
| Receptors, Mitogen | 1 | 2003 | 61 | 0.010 |
Why?
|
| Rats, Zucker | 1 | 2003 | 131 | 0.010 |
Why?
|
| Proteins | 1 | 1998 | 6032 | 0.010 |
Why?
|
| Cyclohexanes | 1 | 2003 | 152 | 0.010 |
Why?
|
| Fluorescein | 1 | 2003 | 175 | 0.010 |
Why?
|
| Maleimides | 1 | 2003 | 113 | 0.010 |
Why?
|
| Eye Burns | 1 | 2003 | 65 | 0.010 |
Why?
|
| alpha-Tocopherol | 1 | 2003 | 126 | 0.010 |
Why?
|
| Predictive Value of Tests | 1 | 2019 | 15266 | 0.010 |
Why?
|
| Oxidants | 1 | 2003 | 169 | 0.010 |
Why?
|
| Syndecans | 1 | 2002 | 75 | 0.010 |
Why?
|
| Staining and Labeling | 1 | 2006 | 1085 | 0.010 |
Why?
|
| Receptors, CCR2 | 1 | 2003 | 215 | 0.010 |
Why?
|
| Sesquiterpenes | 1 | 2003 | 176 | 0.010 |
Why?
|
| Activities of Daily Living | 1 | 2011 | 2421 | 0.010 |
Why?
|
| Burns, Chemical | 1 | 2003 | 123 | 0.010 |
Why?
|
| Molecular Sequence Data | 3 | 2003 | 17635 | 0.010 |
Why?
|
| Prevalence | 1 | 1998 | 15732 | 0.010 |
Why?
|
| Uveitis, Anterior | 1 | 2002 | 102 | 0.010 |
Why?
|
| Syndecan-1 | 1 | 2002 | 163 | 0.010 |
Why?
|
| Glioblastoma | 1 | 1996 | 3482 | 0.010 |
Why?
|
| Protein Biosynthesis | 2 | 2001 | 2113 | 0.010 |
Why?
|
| Galectin 3 | 1 | 2003 | 240 | 0.010 |
Why?
|
| Massachusetts | 1 | 1994 | 8830 | 0.010 |
Why?
|
| Drug Combinations | 2 | 1996 | 2048 | 0.010 |
Why?
|
| Microscopy, Immunoelectron | 1 | 2000 | 317 | 0.010 |
Why?
|
| Incidence | 1 | 1998 | 21353 | 0.010 |
Why?
|
| Hot Temperature | 1 | 2006 | 1440 | 0.010 |
Why?
|
| Gene Targeting | 1 | 2003 | 838 | 0.010 |
Why?
|
| Microscopy, Fluorescence | 1 | 2007 | 2645 | 0.010 |
Why?
|
| Cryosurgery | 2 | 1997 | 474 | 0.010 |
Why?
|
| Apyrase | 1 | 2002 | 373 | 0.010 |
Why?
|
| Anti-Bacterial Agents | 1 | 1998 | 7407 | 0.010 |
Why?
|
| Radiation Injuries | 1 | 2006 | 1189 | 0.010 |
Why?
|
| Axons | 1 | 2007 | 1674 | 0.010 |
Why?
|
| Extracellular Matrix | 1 | 2006 | 1726 | 0.010 |
Why?
|
| Coculture Techniques | 1 | 2002 | 1341 | 0.010 |
Why?
|
| Protein Kinase C | 1 | 2003 | 1202 | 0.010 |
Why?
|
| Melanoma | 1 | 1996 | 5709 | 0.010 |
Why?
|
| Lung Neoplasms | 1 | 2002 | 13380 | 0.010 |
Why?
|
| Injections, Intravenous | 1 | 2000 | 1379 | 0.010 |
Why?
|
| Transgenes | 1 | 2001 | 1010 | 0.010 |
Why?
|
| Thalidomide | 1 | 2002 | 885 | 0.010 |
Why?
|
| Polyhydroxyethyl Methacrylate | 1 | 1996 | 30 | 0.010 |
Why?
|
| Electrophoresis, Agar Gel | 1 | 1996 | 207 | 0.010 |
Why?
|
| Phenotype | 1 | 2014 | 16591 | 0.010 |
Why?
|
| Hepatocytes | 1 | 2003 | 1233 | 0.010 |
Why?
|
| Eye Infections, Parasitic | 1 | 1996 | 26 | 0.010 |
Why?
|
| Porosity | 1 | 1996 | 349 | 0.010 |
Why?
|
| Risk Factors | 1 | 2003 | 74206 | 0.010 |
Why?
|
| Insulin-Like Growth Factor II | 1 | 1997 | 269 | 0.010 |
Why?
|
| Indoles | 1 | 2003 | 1833 | 0.010 |
Why?
|
| Amino Acid Sequence | 2 | 1996 | 13446 | 0.010 |
Why?
|
| Bone Marrow Transplantation | 1 | 2002 | 2693 | 0.010 |
Why?
|
| Cell Proliferation | 1 | 2009 | 10445 | 0.010 |
Why?
|
| Radiography | 1 | 2004 | 6965 | 0.010 |
Why?
|
| Orbit | 1 | 1996 | 457 | 0.010 |
Why?
|
| Mice, Inbred Strains | 1 | 1996 | 1762 | 0.010 |
Why?
|
| Introns | 1 | 1996 | 981 | 0.010 |
Why?
|
| Mice, Inbred BALB C | 1 | 2002 | 6216 | 0.010 |
Why?
|
| Pedigree | 1 | 2001 | 4542 | 0.010 |
Why?
|
| DNA, Complementary | 1 | 1996 | 1991 | 0.010 |
Why?
|
| Brain | 1 | 1999 | 27112 | 0.010 |
Why?
|
| Oxidative Stress | 1 | 2003 | 3113 | 0.010 |
Why?
|
| Sclerosing Solutions | 1 | 1992 | 79 | 0.010 |
Why?
|
| Sequence Homology, Amino Acid | 1 | 1996 | 2748 | 0.010 |
Why?
|
| Hydrogels | 1 | 1996 | 720 | 0.010 |
Why?
|
| Cloning, Molecular | 1 | 1996 | 4174 | 0.010 |
Why?
|
| United States | 1 | 1998 | 72334 | 0.010 |
Why?
|
| Exons | 1 | 1996 | 2391 | 0.010 |
Why?
|
| Laser Therapy | 1 | 1997 | 1092 | 0.010 |
Why?
|
| Terminology as Topic | 1 | 1997 | 1530 | 0.010 |
Why?
|
| Child | 1 | 1998 | 80153 | 0.010 |
Why?
|
| Adolescent | 1 | 1998 | 88319 | 0.010 |
Why?
|
| Liver | 1 | 2003 | 7529 | 0.000 |
Why?
|
| Acute Disease | 1 | 1996 | 7237 | 0.000 |
Why?
|
| Age Factors | 1 | 2001 | 18395 | 0.000 |
Why?
|
| Glucocorticoids | 1 | 1992 | 2161 | 0.000 |
Why?
|
| Diagnosis, Differential | 1 | 1997 | 12974 | 0.000 |
Why?
|
| Chronic Disease | 1 | 1996 | 9318 | 0.000 |
Why?
|
| Genetic Variation | 1 | 1996 | 6567 | 0.000 |
Why?
|
| Prognosis | 1 | 1997 | 29625 | 0.000 |
Why?
|
| Antineoplastic Agents | 1 | 1997 | 13639 | 0.000 |
Why?
|
| Infant | 1 | 1992 | 36192 | 0.000 |
Why?
|